Oncopeptides AB (publ) (ONPPF)
Oncopeptides AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Stockholm, SE. The stock last traded at $0.27, up 0.00% on the session, giving a market capitalisation of $56.0M. On trailing twelve-month figures it carries a trailing P/E of -1.69, a net margin of -265.3%. Its beta of -0.55 implies it has historically moved less than the broad market.
Oncopeptides AB (publ) is a biotechnology company focused on developing pharmaceutical therapies to combat cancer. The firm's therapeutic innovations are intended for markets across the United States, Europe, and internationally. Its flagship product candidate, melflufen, is an advanced anti-cancer peptide drug conjugate specifically designed to treat adult patients afflicted with relapsed refractory multiple myeloma. Oncopeptides AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.
Oncopeptides AB (publ) is most often compared with the following Healthcare names: